FASEB J. Thermo Fisher Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singal, P. K.
Right arrow Articles by Kumar, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singal, P. K.
Right arrow Articles by Kumar, D.

The FASEB Journal, Vol 11, 931-936, Copyright © 1997 by The Federation of American Societies for Experimental Biology

REVIEWS

Adriamycin cardiomyopathy: pathophysiology and prevention

PK Singal, N Iliskovic, T Li and D Kumar
Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, University of Manitoba, Winnipeg, Canada.

Current knowledge about adriamycin cardiomyopathy indicates that the major cause of this condition is increased oxidative stress although the drug's antitumor action in patients may involve other mechanisms. Controversies about the different antioxidants in preventing cardiomyopathy likely stem from the fact that antioxidants must be effective in both the lipid and water phases, and the dose must be optimal, in order to be protective. Probucol, an antioxidant and promoter of endogenous antioxidants, is one such agent. Conducting clinical trials with an optimal dose of probucol is the next step and should make this great anticancer drug safer and more efficient in the fight against the cancer.


This article has been cited by other articles:


Home page
 J BiochemHome page
J. Zhou, Y. Wei, D. Liu, X. Ge, F. Zhou, X. Yun, J. Jiang, and J. Gu
Identification of {beta}1,4GalT II as a Target Gene of p53-mediated HeLa Cell Apoptosis
J. Biochem., April 1, 2008; 143(4): 547 - 554.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Bien, A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al.
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Cancer Res., November 1, 2007; 67(21): 10428 - 10435.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Mol. Interv., June 1, 2007; 7(3): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Xu, H. L. Persson, and D. R. Richardson
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. J. Chicco, C. M. Schneider, and R. Hayward
Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R424 - R431.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Tokarska-Schlattner, M. Zaugg, R. da Silva, E. Lucchinetti, M. C. Schaub, T. Wallimann, and U. Schlattner
Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H37 - H47.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
K. A. Conklin
Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity
Integr Cancer Ther, June 1, 2005; 4(2): 110 - 130.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Middelburg, R. R. de Haas, H. Dekker, R. M. Kerkhoven, P. R. Pohlmann, A. Fuentes-Alburo, A. Mohar, H. M. Pinedo, and J. Lankelma
Induction of p53 Up-Regulated Modulator of Apoptosis Messenger RNA by Chemotherapeutic Treatment of Locally Advanced Breast Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 1863 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
E. KEYHANI and J. KEYHANI
Plasma Membrane Alteration Is an Early Signaling Event in Doxorubicin-Induced Apoptosis in the Yeast Candida utilis
Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 369 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
D. Duquaine, G. A Hirsch, A. Chakrabarti, Z. Han, C. Kehrer, R. Brook, J. Joseph, A. Schott, B Kalyanaraman, J. Vasquez-Vivar, et al.
Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase
Vascular Medicine, May 1, 2003; 8(2): 101 - 107.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
S. Yamanaka, T. Tatsumi, J. Shiraishi, A. Mano, N. Keira, S. Matoba, J. Asayama, S. Fushiki, H. Fliss, and M. Nakagawa
Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes
J. Am. Coll. Cardiol., March 5, 2003; 41(5): 870 - 878.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Shioji, C. Kishimoto, H. Nakamura, H. Masutani, Z. Yuan, S.-i. Oka, and J. Yodoi
Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity
Circulation, September 10, 2002; 106(11): 1403 - 1409.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Tokarska-Schlattner, T. Wallimann, and U. Schlattner
Multiple Interference of Anthracyclines with Mitochondrial Creatine Kinases: Preferential Damage of the Cardiac Isoenzyme and Its Implications for Drug Cardiotoxicity
Mol. Pharmacol., March 1, 2002; 61(3): 516 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Szewczyk and L. Wojtczak
Mitochondria as a Pharmacological Target
Pharmacol. Rev., March 1, 2002; 54(1): 101 - 127.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
E. Rabelo, K. De Angelis, P. Bock, T. Gatelli Fernandes, F. Cervo, A. Bello Klein, N. Clausell, and M. Claudia Irigoyen
Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart Failure
Hypertension, September 1, 2001; 38(3): 576 - 580.
[Abstract] [Full Text]

Home page
 Hum Exp ToxicolHome page
E Breitbart, L Lomnitski, A Nyska, Z Malik, M Bergman, Y Sofer, J K Haseman, and S Grossman
Effects of water-soluble antioxidant from spinach, NAO, on doxorubicin-induced heart injury
Human and Experimental Toxicology, July 1, 2001; 20(7): 337 - 345.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
J. McHowat, L. M. Swift, A. Arutunyan, and N. Sarvazyan
Clinical Concentrations of Doxorubicin Inhibit Activity of Myocardial Membrane-associated, Calcium-independent Phospholipase A2
Cancer Res., May 1, 2001; 61(10): 4024 - 4029.
[Abstract] [Full Text]

Home page
 Cardiovasc ResHome page
T. Li, I. Danelisen, A. Bello-Klein, and P. K. Singal
Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats
Cardiovasc Res, June 1, 2000; 46(3): 523 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Ferraro, L. Quemeneur, A.-F. Prigent, C. Taverne, J.-P. Revillard, and N. Bonnefoy-Berard
Anthracyclines Trigger Apoptosis of Both G0-G1 and Cycling Peripheral Blood Lymphocytes and Induce Massive Deletion of Mature T and B Cells
Cancer Res., April 1, 2000; 60(7): 1901 - 1907.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
M. Arai, A. Yoguchi, T. Takizawa, T. Yokoyama, T. Kanda, M. Kurabayashi, and R. Nagai
Mechanism of Doxorubicin-Induced Inhibition of Sarcoplasmic Reticulum Ca2+-ATPase Gene Transcription
Circ. Res., January 7, 2000; 86(1): 8 - 14.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. K. Seneviratne, T. Li, N. Khaper, and P. K. Singal
Effects of methionine on endogenous antioxidants in the heart
Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2124 - H2128.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. ANDRIEU-ABADIE, J.-P. JAFFRÉZOU, S. HATEM, G. LAURENT, T. LEVADE, and J.-J. MERCADIER
L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation
FASEB J, September 1, 1999; 13(12): 1501 - 1510.
[Abstract] [Full Text]

Home page
 Cardiovasc ResHome page
P. K Singal, N. Khaper, V. Palace, and D. Kumar
On the role of coenzyme Q10 in cardiovascular diseases
Cardiovasc Res, July 1, 1999; 43(1): 250 - 251.
[Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. KUMAR, L. KIRSHENBAUM, T. LI, I. DANELISEN, and P. SINGAL
Apoptosis in Isolated Adult Cardiomyocytes Exposed to Adriamycin
Ann. N.Y. Acad. Sci., June 30, 1999; 874(1): 156 - 168.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ravid, D. Rocker, A. Machlenkin, C. Rotem, A. Hochman, G. Kessler-Icekson, U. A. Liberman, and R. Koren
1,25-Dihydroxyvitamin D3 Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage
Cancer Res., February 1, 1999; 59(4): 862 - 867.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
G. MINOTTI, G. CAIRO, and E. MONTI
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
FASEB J, February 1, 1999; 13(2): 199 - 212.
[Abstract] [Full Text]

Home page
 CirculationHome page
V. P. Palace, M. F. Hill, F. Farahmand, and P. K. Singal
Mobilization of Antioxidant Vitamin Pools and Hemodynamic Function After Myocardial Infarction
Circulation, January 12, 1999; 99(1): 121 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. K Singal, N. Khaper, V. Palace, and D. Kumar
The role of oxidative stress in the genesis of heart disease
Cardiovasc Res, December 1, 1998; 40(3): 426 - 432.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. K. Singal and N. Iliskovic
Doxorubicin-Induced Cardiomyopathy
N. Engl. J. Med., September 24, 1998; 339(13): 900 - 905.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by The Federation of American Societies for Experimental Biology.